Dupilumab Anti-interleukin-4 receptor α (Anti-IL-4Rα), investigated in the Liberty Asthma QUEST 2021 Phase 3 trial [28] and TRAVERSE open-label extension [29], produced similar results, where 31.7% of the subjects reached the endpoint of improved symptom control and better pulmonary function following 12 months of treatment. Here, IL4R is linked to asthma.